• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·AARTIDRUGS.NS
Share

Aarti Drugs Limited Stocks

₹ 432.8Last Updated 10.09.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

₹ 420.05M

₹ 432.8
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating both within India and globally, Aarti Drugs Limited, along with its affiliated companies, specializes in the pharmaceutical sector. Its product portfolio encompasses a wide range of active pharmaceutical ingredients (APIs) across numerous therapeutic areas, such as anti-inflammatory, cardiovascular protection, antidiarrheal, antifungal, anti-arthritis/osteoporosis, antibiotic, antidiabetic, Alzheimer's disease management, sedative, vitamin, and alcoholism treatment. Additionally, it supplies pharmaceutical intermediate compounds, including tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. Furthermore, the company manufactures and distributes various specialty chemicals. These include a comprehensive list of compounds such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, sodium benzene sulfinate, para toluene sulphonyl hydrazide, benzene sulphonic acid and its sodium salt, benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. Aarti Drugs also maintains a robust development pipeline, featuring products such as Acamprosate, intended for treating alcoholism; Dabigatran, an anticoagulant; Sevelamer, for managing hyperphosphatemia; Colesevelam, aimed at lowering cholesterol; Dronedarone and Olmesartan, both for cardiovascular disease treatment; Valsartan, which acts as a cardioprotectant; and Sitagliptin, an antidiabetic agent. Moreover, the firm provides contract manufacturing solutions. Established in 1984, the company's main operations are based in Mumbai, India.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair value on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of AARTIDRUGS.NS is 439 and suggests 3.67% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recom

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.09.2026 21:24

The owner of Vimeo has agreed to acquire Miro, a company with Russian roots, for $1.4 billion

10.09.2026 20:22

Europe's largest airline has warned of the risk of a "significant increase" in prices due to oil prices

10.09.2026 19:47

A Historic Shift: BlackRock Proposes an Alternative to the 60/40 Portfolio

10.09.2026 19:09

"A Bit of Chaos": How Sergey Brin Is Building Gemini in Startup Style in a Kitchen at Google

10.09.2026 18:40

The Nasdaq fell 1% at the start of trading in the U.S. due to a sharp rise in oil prices

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026